(Q33418868)

26 July 2017

title

Combination of docetaxel, ifosfamide and cisplatin (DIP) as a potential salvage chemotherapy for metastatic urothelial carcinoma (English)

1 reference

26 July 2017

1 reference

1 reference

1 reference

11

Yasuhiko Igawa

1 reference

26 July 2017

12

Yukio Homma

1 reference

26 July 2017

10

Haruki Kume

1 reference

26 July 2017

8

Tetsuya Fujimura

1 reference

26 July 2017

2

Hiroshi Fukuhara

1 reference

26 July 2017

9

Tohru Nakagawa

1 reference

26 July 2017

5

Aya Niimi

1 reference

26 July 2017

Shigenori Kakutani

1

1 reference

26 July 2017

Satoru Taguchi

3

1 reference

26 July 2017

Masayoshi Nagata

4

1 reference

26 July 2017

Mami Hattori

6

1 reference

26 July 2017

Hideyo Miyazaki

7

1 reference

26 July 2017

language of work or name

1 reference

25 November 2014

1 reference

Japanese Journal of Clinical Oncology

26 July 2017

published in

1 reference

26 July 2017

volume

45

1 reference

26 July 2017

issue

3

1 reference

26 July 2017

page(s)

281-285

1 reference

Cancer incidence and incidence rates in Japan in 2008: a study of 25 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project

26 July 2017

cites work

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Long-term survival results of a randomized trial comparing gemcitabine plus cisplatin, with methotrexate, vinblastine, doxorubicin, plus cisplatin in patients with bladder cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Second-line systemic therapy and emerging drugs for metastatic transitional-cell carcinoma of the urothelium

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Docetaxel (Taxotere): an active agent in metastatic urothelial cancer; results of a phase II study in non-chemotherapy-pretreated patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Phase II multicentre study of docetaxel plus cisplatin in patients with advanced urothelial cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Docetaxel and ifosfamide as second line treatment for patients with advanced or metastatic urothelial cancer after failure of platinum chemotherapy: a phase 2 study

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Combination chemotherapy of docetaxel, ifosfamide and cisplatin (DIP) in patients with metastatic urothelial cancer: a preliminary report

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Prediction of creatinine clearance from serum creatinine

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Paclitaxel, ifosfamide, and nedaplatin as second-line treatment for patients with metastatic urothelial carcinoma: a phase II study of the SUOC group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Prognostic factors for metastatic urothelial carcinoma undergoing cisplatin-based salvage chemotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Time from prior chemotherapy enhances prognostic risk grouping in the second-line setting of advanced urothelial carcinoma: a retrospective analysis of pooled, prospective phase 2 trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

Docetaxel and cisplatin combination chemotherapy in advanced carcinoma of the urothelium: A multicenter phase II study of the Hellenic Cooperative Oncology Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1093%2FJJCO%2FHYU201

21 January 2018

Identifiers

DOI

10.1093/JJCO/HYU201

1 reference

26 July 2017

1 reference